225Actinium-PSMA-I&T

N/A

Report date: 2026/01/04 10:45:54

NME

Base Information

Drug Name225Actinium-PSMA-I&T

Drug Alias NameAc225-PSMA I&TAc225-PSMAFPI-2265

ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radionuclide Drug Conjugates +[5]

Mechanisms of ActionIonising radiation emittersPositron-emission tomography enhancersAnti-PSMA

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesExcel Diagnostics And Nuclear Oncology Center

China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-Resistant

Inactive IndicationsN/A

Other Information

ATC CodeN/A